Abrilumab (INN; development code AMG 181) is a monoclonal antibody designed for the treatment of inflammatory bowel disease, ulcerative colitis, and Crohn's disease.Statement On A Nonproprietary Name Adopted By The USAN Council - Abrilumab, American Medical Association.
This drug was developed by MedImmune.
References